

# Clara Allayous

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9753683/publications.pdf>

Version: 2024-02-01

9  
papers

231  
citations

1478505

6  
h-index

1588992

8  
g-index

9  
all docs

9  
docs citations

9  
times ranked

375  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 836-847.	10.7	104
2	Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. , 2021, 9, e002121.		30
3	Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort. <i>European Journal of Cancer</i> , 2019, 112, 38-46.	2.8	27
4	Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection. <i>Science Advances</i> , 2021, 7, .	10.3	27
5	Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-“PD-1 Therapy. <i>JCO Precision Oncology</i> , 2021, 5, 1821-1829.	3.0	17
6	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. <i>European Journal of Cancer</i> , 2021, 151, 72-83.	2.8	12
7	Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival. <i>JAMA Dermatology</i> , 2019, 155, 673.	4.1	7
8	Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases. <i>Cancers</i> , 2020, 12, 2635.	3.7	5
9	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply. <i>Lancet Oncology</i> , The, 2021, 22, e343-e344.	10.7	2